Rajeev Gautam
Overview
Explore the profile of Rajeev Gautam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1782
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferguson S, Rothermel A, Rohan P, Gautam R, Hodge D
Nat Immunol
. 2025 Jan;
26(2):161-164.
PMID: 39856424
No abstract available.
2.
Schleiss M, Crooks C, Karthigeyan K, Kruc R, Otero C, Wang H, et al.
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591134
Congenital cytomegalovirus (cCMV) is the most common infectious cause of disability in children, including sensorineural hearing loss. There is interest in developing a pre-conception vaccine that could confer protective immunity...
3.
Pesch M, Schleiss M, Plotkin S, Permar S, Gautam R
Vaccines (Basel)
. 2024 Nov;
12(11).
PMID: 39591129
Congenital cytomegalovirus (cCMV) is the most common infectious cause of disability in children. The major theme of this National Institute of Allergy and Infectious Diseases (NIAID) workshop, "CMV Vaccine Development-How...
4.
Apetrei C, Gaufin T, Brocca-Cofano E, Sivanandham R, Sette P, He T, et al.
JCI Insight
. 2023 Jul;
8(14).
PMID: 37485874
Resolution of T cell activation and inflammation is a key determinant of the lack of SIV disease progression in African green monkeys (AGMs). Although frequently considered together, T cell activation...
5.
Hartweger H, Gautam R, Nishimura Y, Schmidt F, Yao K, Escolano A, et al.
J Vis Exp
. 2023 Feb;
(192).
PMID: 36847375
B cells and their progeny are the sources of highly expressed antibodies. Their high protein expression capabilities together with their abundance, easy accessibility via peripheral blood, and amenability to simple...
6.
Yang Z, Dam K, Bridges M, Hoffmann M, DeLaitsch A, Gristick H, et al.
Nat Commun
. 2022 Feb;
13(1):732.
PMID: 35136084
Broadly-neutralizing antibodies (bNAbs) against HIV-1 Env can protect from infection. We characterize Ab1303 and Ab1573, heterologously-neutralizing CD4-binding site (CD4bs) antibodies, isolated from sequentially-immunized macaques. Ab1303/Ab1573 binding is observed only when...
7.
Zhang P, Narayanan E, Liu Q, Tsybovsky Y, Boswell K, Ding S, et al.
Nat Med
. 2021 Dec;
27(12):2234-2245.
PMID: 34887575
The development of a protective vaccine remains a top priority for the control of the HIV/AIDS pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing membrane-anchored HIV-1 envelope...
8.
Escolano A, Gristick H, Gautam R, DeLaitsch A, Abernathy M, Yang Z, et al.
Sci Transl Med
. 2021 Nov;
13(621):eabk1533.
PMID: 34818054
Broadly neutralizing antibodies (bNAbs) against HIV-1 develop after prolonged virus and antibody coevolution. Previous studies showed that sequential immunization with a V3-glycan patch germline-targeting HIV-1 envelope trimer (Env) followed by...
9.
Abernathy M, Gristick H, Vielmetter J, Keeffe J, Gnanapragasam P, Lee Y, et al.
NPJ Vaccines
. 2021 Oct;
6(1):126.
PMID: 34697307
HIV-1 vaccine design aims to develop an immunogen that elicits broadly neutralizing antibodies against a desired epitope, while eliminating responses to off-target regions of HIV-1 Env. We report characterization of...
10.
Wang Z, Barnes C, Gautam R, Cetrulo Lorenzi J, Mayer C, Oliveira T, et al.
Elife
. 2020 Oct;
9.
PMID: 33084569
A small fraction of HIV-1- infected humans develop broadly neutralizing antibodies (bNAbs) against HIV-1 that protect macaques from simian immunodeficiency HIV chimeric virus (SHIV). Similarly, a small number of macaques...